专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

KR101429668B1 양친성 저분자량 히알루론산 복합체를 포함하는 나노 입자 및 그의 제조 방법 有权
标题翻译：包含两亲低分子量透明质酸络合物的纳米颗粒及其制备方法
公开(公告)号：KR101429668B1
公开(公告)日：2014-08-14
申请号：KR1020130123611
申请日：2013-10-16
申请人： 씨제이헬스케어 주식회사
发明人： 김유미 , 윤명식 , 이하영 , 임동권 , 임선경 , 기소영 , 김세환 , 박지은 , 박지혜 , 이정록 , 이주현 , 조일환 , 홍은미 , 홍혜숙
IPC分类号： A61K47/48 , A61K47/36 , A61K47/30 , A61K9/16
摘要： 본 발명은 5 내지 20 KDa의 저분자량 히알루론산에 소수성 담즙산이 결합되어 수중에서 자기 집합체(self-aggregation)를 형성하는 히알루론산-담즙산 복합체, 상기 복합체 내부에 소수성 약물이 봉입된 나노입자, 그 나노입자를 포함하는 주사제, 및 그 나노입자의 제조방법을 제공한다.

2. 发明授权

KR101414897B1 다베포에틴 알파의 정제 방법 有权
标题翻译：一种用于纯化达巴非汀ALFA的方法
公开(公告)号：KR101414897B1
公开(公告)日：2014-07-04
申请号：KR1020130148026
申请日：2013-11-29
申请人： 씨제이헬스케어 주식회사
发明人： 이윤정 , 김경화 , 양유희 , 유정민 , 김세준 , 문지현 , 오후근 , 이동억 , 이원정 , 이정록 , 이정민 , 최은영 , 하경식
IPC分类号： C07K1/18 , C07K14/505
CPC分类号： C07K14/505 , C07K1/18
摘要： The present invention relates to a darbepoetin alpha refining method which selectively separates only a structural form having a high content of high sialic acid from a mixture of the structural form of a darbepoetin alpha having various sialic acid contents. The new barbepoetin alpha refining method of the present invention, which is convenient and easy to be applied to a production, is able to not only obtain the darbepoetin alpha with high purity but also remarkably increase productivity in response to the improvement of process efficiency when manufacturing the bardepoetin alpha in bulk by the present invention.
摘要翻译：本发明涉及一种达贝泊汀α精制方法，其从具有各种唾液酸含量的达贝泊汀α的结构形式的混合物中仅选择性分离具有高唾液酸含量的结构形式。方便，易于应用于生产的本发明的新的巴巴培丁α精制方法不仅可以获得高纯度的达贝泊汀α，而且可以显着提高生产率，以提高生产过程中的工艺效率本发明的散在的bardepoetinα。

3. 发明公开

KR1020130117361A 양친성 저분자량 히알루론산 복합체를 포함하는 나노 입자 및 그의 제조 방법 有权
标题翻译：包含高分子量低分子量羟基丙酸复合物的纳米颗粒及其制备方法
公开(公告)号：KR1020130117361A
公开(公告)日：2013-10-25
申请号：KR1020130123611
申请日：2013-10-16
申请人： 씨제이헬스케어 주식회사
发明人： 김유미 , 윤명식 , 이하영 , 임동권 , 임선경 , 기소영 , 김세환 , 박지은 , 박지혜 , 이정록 , 이주현 , 조일환 , 홍은미 , 홍혜숙
IPC分类号： A61K47/48 , A61K47/36 , A61K47/30 , A61K9/16
CPC分类号： A61K9/1617 , A61K9/1652 , A61K47/28 , A61K47/36 , B82Y5/00
摘要： PURPOSE: A nanoparticle containing a low molecular weight amphiphilic hyaluronic acid composite is provided to show superior water solubility compared with an existing drug delivery system and to encapsulate high volume drugs with high efficiency. CONSTITUTION: A low molecular weight hyaluronic acid-5-beta cholanic acid composite is an amphiphilic composite in which 5-beta-cholanic acid is conjugated to hyaluronic acid with a molecular weight of 5-20 kDa. The composite forms self-aggregates in water. Nanoparticles are formed by encapsulating a hydrophobic drug in the composite. A method for preparing the nanoparticles comprises the steps of: synthesizing 5-beta cholanic acid with a cholanic acid structure using aminoethyl cholanoamide; dissolving the hyaluronic acid with a molecular weight of 5-20 kDa in an aqueous solvent to prepare a hyaluronic acid solution; dissolving aminoethyl cholanoamide in an organic solvent to prepare a cholanoamide solution; adding the cholanoamide solution to the hyaluronic acid solution and preparing a reactant solution; depositing the hyaluronic acid-5-beta cholanic acid composite from the reactant solution; and encapsulating a drug in the hyaluronic acid-5-beta cholanic acid.
摘要翻译：目的：提供含有低分子量两亲透明质酸复合材料的纳米粒子，与现有的药物输送系统相比显示出优异的水溶性，并且以高效率包封大量药物。构成：低分子量透明质酸-5-β胆酸复合物是两亲性复合物，其中5-β-胆酸与分子量为5-20kDa的透明质酸缀合。复合物在水中形成自聚集体。通过将疏水性药物包封在复合材料中形成纳米颗粒。制备纳米颗粒的方法包括以下步骤：使用氨基乙基胆酰胺合成具有胆酸结构的5-β胆酸; 将分子量为5-20kDa的透明质酸溶解在水性溶剂中以制备透明质酸溶液; 将氨基乙基胆酰胺溶解在有机溶剂中以制备胆酰胺溶液; 将胆酰胺溶液加入到透明质酸溶液中并制备反应物溶液; 从反应物溶液沉积透明质酸-5-β胆酸复合物; 并将药物包封在透明质酸-5-β胆酸中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式